Prasterone vs Vaginal Estradiol: Which Treats GSM Better?
A clinical comparison of prasterone (Intrarosa) and vaginal estradiol for genitourinary syndrome of menopause, covering mechanism, efficacy data, safety, cost, and how to choose.
PT-141 Nausea and Skin Pigmentation: What Patients Need to Know
PT-141 (bremelanotide) causes nausea in up to 40% of users and transient skin darkening in roughly 1 in 7 women. Learn the mechanisms, management strategies, and how Addyi's alcohol restriction compares.
Trazodone for Sexual Function in Women: What the Evidence Actually Shows
A clinical review of trazodone's off-label use for female sexual dysfunction, with an honest look at the limited trial evidence, compared against FDA-approved options: flibanserin, bremelanotide, vaginal estradiol, and vaginal DHEA (prasterone).
Zepbound Cognitive Function Impact: What the Evidence Shows
A deep dive into tirzepatide's effects on cognition, brain inflammation, and neurological markers, with primary-literature citations and clinical guidance.
Zepbound for Fatty Liver: Dosing in Hepatic Impairment
No dose adjustment is needed for Zepbound in mild, moderate, or severe liver impairment. Standard titration from 2.5 mg weekly still applies, per PK study data.
Zepbound Pharmacokinetics (ADME): How Tirzepatide Is Absorbed, Distributed, Metabolized, and Excreted
A clinician-level breakdown of Zepbound (tirzepatide) pharmacokinetics, covering absorption after subcutaneous injection, protein binding, metabolic pathways, half-life, and renal/hepatic excretion, with citations to FDA labeling, SURMOUNT-1, and primary PK studies.
Zepbound Switching: How to Transition From or To Other GLP-1/GIP Drugs Safely
A guide to switching between Zepbound (tirzepatide) and other weight-loss medications in the same class, including semaglutide, liraglutide, and oral GLP-1 agents. Covers mechanism, dosing bridging strategies, and clinical evidence.
Zepbound Monitoring for Young Adults (Ages 18 to 29): What to Track and When
A complete clinical guide to monitoring tirzepatide (Zepbound) in young adults aged 18, 29, covering labs, vitals, fertility, mental health, and dose-escalation checkpoints.
Zepbound Appetite & Cravings Changes: What the Evidence Actually Shows
A clinician-oriented review of how Zepbound (tirzepatide) affects appetite, food cravings, and eating behavior, with attention to what is established by trial evidence versus what remains mechanistic hypothesis.
Zepbound Autoimmune Disease Considerations: What Patients and Clinicians Need to Know
A guide to using Zepbound (tirzepatide) in patients with autoimmune disease, covering immunologic mechanisms, disease-specific risks, drug interactions, and monitoring questions clinicians should raise before prescribing.
Zepbound Bone Health and Density Impact: What the Evidence Shows
A clinical deep-dive into how tirzepatide (Zepbound) affects bone mineral density, fracture risk, and bone turnover markers, with primary-literature citations and practical monitoring guidance.
Zepbound After Bariatric Surgery: What Patients and Clinicians Need to Know
A clinical deep-dive into tirzepatide (Zepbound) use after bariatric surgery, covering pharmacokinetics, dosing, safety, and the evidence base for post-bariatric GLP-1/GIP therapy.
Restarting Zepbound After Illness: Timing, Symptoms, and Next Steps
Restarting Zepbound after food poisoning, COVID-19, or surgery: what changes the decision, why there is no fixed dose-step rule, and what to ask your prescriber.
Reclast (Zoledronic Acid) Autoimmune Disease Considerations
MD/PharmD-level review of zoledronic acid use in autoimmune disease: fracture data from HORIZON-PFT, immunomodulatory mechanisms, drug interactions with DMARDs and biologics, and dosing guidance for patients on corticosteroids.
Reclast (Zoledronic Acid) Complete Drug-Drug Interaction Profile
A PubMed-cited guide to every clinically significant drug-drug interaction with zoledronic acid (Reclast), including aminoglycosides, NSAIDs, loop diuretics, antiangiogenics, and more.
Reclast (Zoledronic Acid) Rebound Effects When Stopping
What happens to bone turnover and fracture risk after stopping zoledronic acid (Reclast)? A primary-literature-based guide covering offset timing, rebound markers, and evidence-based transition protocols.
Reclast (Zoledronic Acid) Hair and Skin Changes: What Patients and Clinicians Need to Know
A clinical deep-dive into zoledronic acid (Reclast) hair loss and skin reactions, covering incidence data, mechanisms, management, and when to escalate care.
Is Zolpidem Cognitive Impairment Reversible After Stopping?
Zolpidem impairs memory and psychomotor speed via GABA-A activity; impairment is dose-dependent and can persist 8 hours post-dose, per FDA data.
Ambien Complete Drug-Drug Interaction Profile: What Clinicians and Patients Need to Know
An evidence-based breakdown of every clinically significant zolpidem drug-drug interaction, including CNS depressants, CYP3A4 inhibitors, alcohol, and more. Includes real trial data, FDA guidance, and dosing adjustments.
Ambien Hair and Skin Changes: What Zolpidem Actually Does to Your Body
A guide to zolpidem (Ambien) and its documented effects on hair and skin, including telogen effluvium, pruritus, urticaria, and angioedema, with primary-literature citations and dose-specific guidance.
Ambien Pre-Surgery Hold Window: How Long Before Your Procedure Should You Stop Zolpidem?
Board-reviewed clinical guide on the zolpidem pre-surgery hold window: recommended stop times, anesthesia interaction risks, rebound insomnia management, and when to restart after your procedure.
Switching To or From Zolpidem (Ambien): A Protocol
A guide to switching zolpidem (Ambien) to or from other sedative-hypnotics, covering mechanism, cross-tolerance, taper schedules, and drug-specific transition protocols with primary-source citations.
Adderall XR: What to Expect, Week-by-Week First Month
A week-by-week clinical guide to Adderall XR (mixed amphetamine salts extended-release) in the first month: onset timing, dose titration, side effects, and what your prescriber watches for at each follow-up visit.
Trulicity Geriatric (65+) Caregiver Administration Guidance
A complete clinical guide for caregivers administering dulaglutide (Trulicity) to adults aged 65 and older, covering injection technique, dose timing, hypoglycemia risk, storage, and monitoring protocols reviewed by board-certified physicians.
Amlodipine Renal Protection or Renal Risk: What the Evidence Actually Shows
Does amlodipine protect the kidneys or harm them? A clinician-level review of ASCOT-BPLA, AASK, ACCOMPLISH, and newer data on proteinuria, GFR trends, and when to combine amlodipine with a renin-angiotensin blocker.
AndroGel Seasonal Use Considerations: A Clinical Guide
How temperature, sweat, humidity, and seasonal vitamin D shifts affect AndroGel (testosterone gel 1% and 1.62%) absorption, dosing, and monitoring. Evidence-based guidance from the T-Trials and current Endocrine Society guidelines.
SARM HPG Axis Suppression: Liver Toxicity, Cardiac Risks, and What the Evidence Shows
A clinical deep-dive into how SARMs suppress the hypothalamic-pituitary-gonadal axis, damage the liver, and stress the heart. Learn what the research actually says about dosing, recovery, and risk reduction.
Function Health Pricing Analysis & Total Cost: Is It Worth It in 2025?
An independent pricing analysis of Function Health's subscription model, lab panel value, and total annual cost versus alternatives. prepared by the HealthRX.com Editorial Team.
Gennev Ideal Patient Profile: Who Gets the Most From This Menopause Platform
An evidence-based analysis of who Gennev is best suited for, what it prescribes, how much it costs, and how it compares to alternatives for managing menopause symptoms.
TrimRx Company Overview & Business Model: Is It Legit?
An evidence-based review of TrimRx, the compounded GLP-1 telehealth brand. Learn how it works, what it costs, how it compares to alternatives, and what the clinical evidence says about compounded semaglutide and tirzepatide.
Does Anthem (Elevance Health) Cover Vyleesi (Bremelanotide)?
A clinical and insurance guide to Anthem (Elevance Health) coverage of Vyleesi (bremelanotide) for HSDD, including prior authorization criteria, step therapy requirements, appeal strategies, and cost alternatives.
Vyleesi Renal Protection or Renal Risk: What Patients and Prescribers Need to Know
A deep dive into bremelanotide (Vyleesi) and renal function: pharmacokinetics, clinical trial safety data, FDA labeling guidance, and practical prescribing advice for patients with kidney concerns.
Vyleesi Safety Signals & FDA Actions: What Prescribers and Patients Need to Know
A clinician-level review of bremelanotide (Vyleesi) safety signals, FDA actions, post-marketing data, and the melanocortin mechanism behind HSDD treatment in premenopausal women.
GLP-1 Receptor Agonists Special Populations: A Prescriber's Summary
A clinical-level review of GLP-1 receptor agonist use across special populations, pregnancy, renal impairment, heart failure, pediatrics, and more, with dosing guidance, trial data, and guideline citations.
GH Secretagogue Guide: Which One to Pick
Ipamorelin, sermorelin, CJC-1295, GHRP-6, and MK-677 compared by pulsatility, cortisol/prolactin effects, route, and goal to guide agent selection.
Saxenda vs Trulicity Side Effects: A Head-to-Head Profile
A detailed comparison of liraglutide 3 mg (Saxenda) and dulaglutide (Trulicity) side-effect profiles, drawn from SCALE, REWIND, and current prescribing guidelines.
Zepbound vs Liraglutide: Switching Between Them
A clinical comparison of tirzepatide (Zepbound) and liraglutide, covering efficacy data from SURMOUNT-1 and SCALE Obesity, practical switching protocols, and when each drug fits best.
Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): Head-to-Head Efficacy
A clinical comparison of vardenafil and alprostadil for erectile dysfunction: efficacy data, trial results, mechanism differences, and guidance on which drug fits which patient.
BPC-157 vs GHK-Cu: Cost and Access Head-to-Head
A direct comparison of BPC-157 pentadecapeptide and GHK-Cu copper tripeptide covering mechanism, evidence quality, dosing, cost, and legal access in 2025.
NAFLD / MASLD Diagnostic Algorithm, Step by Step
A step-by-step diagnostic algorithm for NAFLD/MASLD: who to screen, which tests to order, how to stage fibrosis, and when to refer for liver biopsy or specialist care.
PCOS Racial and Ethnic Disparities: What the Evidence Shows
A comprehensive, evidence-based review of how PCOS diagnosis, symptoms, and treatment outcomes differ across racial and ethnic groups, with clinical guidance for equitable care.
Perimenopause Racial and Ethnic Disparities: What the Evidence Shows
Black, Hispanic, and Asian women experience perimenopause differently from white women in symptom burden, duration, and access to care. Learn what the research shows and what clinical guidelines recommend.
Trulicity for Metabolic Syndrome: Evidence, Dosing, and What to Expect
A guide to using dulaglutide (Trulicity) for metabolic syndrome: trial evidence, dosing schedules, cardiovascular outcomes, and practical protocols.
Avodart Autoimmune Disease Considerations: What Clinicians and Patients Need to Know
A clinician-level review of dutasteride (Avodart) and autoimmune disease: drug-induced lupus risk, thyroid interactions, immunomodulatory mechanisms, dosing cautions, and how to monitor patients with pre-existing autoimmune conditions.
Epitalon Autoimmune Disease Considerations: What the Clinical Evidence Shows
A guide to epitalon tetrapeptide and autoimmune disease considerations, covering immunomodulatory mechanisms, telomerase biology, clinical trial data, and safety signals relevant to patients with autoimmune conditions.
Estradiol Patch Bone Health and Density Impact
A clinical deep-dive into how estradiol transdermal patches preserve and restore bone mineral density in postmenopausal women, covering trial data, mechanisms, dosing, and monitoring protocols.
Mounjaro South Asian Documented Efficacy Gaps
A clinical deep-dive into tirzepatide (Mounjaro) efficacy differences in South Asian patients: subgroup data, pharmacogenomics, BMI thresholds, and dosing considerations prepared by the HealthRX.com Editorial Team.
Topical Minoxidil East Asian Safety Profile Differences
A guide to how topical minoxidil 5% behaves differently in East Asian patients, covering pharmacogenomics, CYP2C19/CYP2D6 variation, ethnicity-stratified trial data, and dosing considerations.
Vaginal Estradiol South Asian Dose Adjustments: What the Evidence Actually Shows
South Asian women may need tailored vaginal estradiol dosing due to pharmacogenomic differences, earlier menopause onset, and cardiovascular risk at lower BMI. This HealthRX.com guide covers ethnicity-specific dose adjustment evidence, CYP19A1 variants, and clinical decision frameworks.
Wegovy South Asian Documented Efficacy Gaps: What the Data Actually Show
South Asian patients using Wegovy (semaglutide 2.4 mg) may see smaller percentage weight loss than trial averages suggest. Here is what ethnicity-stratified subgroup data, pharmacogenomic research, and revised BMI thresholds tell clinicians and patients.
Repatha Appetite & Cravings Changes: What the Evidence Actually Shows
Does evolocumab (Repatha) affect appetite or food cravings? A clinician-level review of FOURIER trial data, PCSK9 biology, lipid-appetite signaling, and what patients and prescribers should expect.
Finasteride Overdose and Accidental Excess Dose: What Clinicians and Patients Need to Know
A guide to finasteride overdose, accidental excess dosing, mechanism of action, and 5-alpha reductase inhibition, with FDA-cited evidence and toxicology data.
Finasteride Cognitive Function Impact: What the Evidence Actually Shows
A clinician-level review of finasteride's effects on cognition, neurosteroid pathways, post-finasteride syndrome, and what current evidence says about memory, brain fog, and mood.
Does UnitedHealthcare Cover Addyi (Flibanserin)?
A guide to UnitedHealthcare coverage for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary tier placement, appeals, and cost-saving strategies for HSDD treatment.
GLP-1 and NAION Vision: What the Evidence Actually Says About Eye Risk
A guide to non-arteritic anterior ischemic optic neuropathy (NAION) and GLP-1 receptor agonists. Learn who is at risk, what the data show, and what to do if your vision changes on semaglutide or tirzepatide.
STEP 5 Trial: Two-Year Semaglutide Weight Loss Results Explained
STEP 5, published in Nature Medicine in 2022, found semaglutide 2.4 mg gave 15.2% mean weight loss at 104 weeks versus 2.6% placebo in 304 adults, no T2D.
Can Ozempic® Lower My Risk for Major Cardiovascular Events?
A deep dive into the SUSTAIN-6 and SELECT trials showing how semaglutide reduces heart attack, stroke, and cardiovascular death risk in adults with type 2 diabetes or obesity.
Does Amerigroup Cover Liraglutide (Saxenda)?
A full breakdown of Amerigroup Medicaid and Medicare Advantage coverage for liraglutide (Saxenda), including prior authorization steps, formulary tiers, appeal strategies, and cost-saving alternatives.
What Are the Common Side Effects of Saxenda®?
A guide to Saxenda® (liraglutide 3.0 mg) side effects, their frequency, duration, and how to manage them safely during weight-loss treatment.
What Are Some Foods & Eating Tips for Mounjaro Users?
A guide to meal composition, portion size, and timing strategies for people taking Mounjaro (tirzepatide), organized around the drug's known effect on gastric emptying and appetite.